MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318654 | Name: Reboxetine Mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Reboxetine is an antidepressant compound that selectively inhibits norepinephrine uptake for norepinephrine and serotonin transporters.

Chemical Structure

Reboxetine Mesylate
Reboxetine Mesylate
CAS# 98769-84-7

Theoretical Analysis

MedKoo Cat#: 318654

Name: Reboxetine Mesylate

CAS#: 98769-84-7

Chemical Formula: C20H27NO6S

Exact Mass: 0.0000

Molecular Weight: 409.50

Elemental Analysis: C, 58.66; H, 6.65; N, 3.42; O, 23.44; S, 7.83

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Reboxetine Mesylate; Reboxetine mesilate; Reboxetine (mesylate); Edronax; PNU 155950E;Reboxetine mesylate; Vestra (TN); AC1L2RIX; AC1Q6WCV; DSSTox_CID_25690; DSSTox_RID_81062; DSSTox_GSID_45690;
IUPAC/Chemical Name
(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid
InChi Key
XNHPNCDIRBAKCQ-WOJBJXKFSA-N
InChi Code
InChI=1S/C20H25NO6S/c1-2-25-17-10-6-7-11-18(17)27-20(16-8-4-3-5-9-16)19-14-21(12-13-26-19)15-28(22,23)24/h3-11,19-20H,2,12-15H2,1H3,(H,22,23,24)/t19-,20-/m1/s1
SMILES Code
CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Reboxetine selectively inhibits norepinephrine uptake (IC50s = 8.2 and 1,070 nM for norepinephrine and serotonin transporters, respectively). It displays >1,000-fold affinity for binding rat norepinephrine receptors compared to serotonin, histamine, acetylcholine, or dopamine receptors (Kis = 1.1, 129, 1,400, 3,900, and >10,000 nM, respectively).
In vitro activity:
The results of this study support the potential of reboxetine as an anti-Candidal biofilm agent that is beneficial as a new antifungal to combat Candidal resistance. Reference: Antibiotics (Basel). 2023 May 9;12(5):881. https://pubmed.ncbi.nlm.nih.gov/37237784/
In vivo activity:
Reboxetine and hyoscine butylbromide significantly reduced rapid eye movement sleep compared with placebo. Genioglossus muscle activity (% wakefulness) during non-REM sleep was lower with reboxetine and hyoscine butylbromide. However, sleep-related reductions in tensor palatini activity were less and upper airway function improved. Reference: Sleep. 2019 Apr 1;42(4):zsy261. https://pubmed.ncbi.nlm.nih.gov/30590857/
Solvent mg/mL mM
Solubility
Water 20.5 50.00
DMSO 20.5 50.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 409.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ahmed EI, Alhuwaydi AM, Taha AE, Abouelkheir M. Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms. Antibiotics (Basel). 2023 May 9;12(5):881. doi: 10.3390/antibiotics12050881. PMID: 37237784; PMCID: PMC10215628. 2. Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO. Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan;344(1):113-23. doi: 10.1124/jpet.112.197905. Epub 2012 Sep 25. PMID: 23010362. 3. Lim R, Carberry JC, Wellman A, Grunstein R, Eckert DJ. Reboxetine and hyoscine butylbromide improve upper airway function during nonrapid eye movement and suppress rapid eye movement sleep in healthy individuals. Sleep. 2019 Apr 1;42(4):zsy261. doi: 10.1093/sleep/zsy261. PMID: 30590857; PMCID: PMC8453808. 4. Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka DT. Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers. J Psychiatry Neurosci. 2014 May;39(3):E24-31. doi: 10.1503/jpn.130131. PMID: 24467942; PMCID: PMC3997609.
In vitro protocol:
1. Ahmed EI, Alhuwaydi AM, Taha AE, Abouelkheir M. Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms. Antibiotics (Basel). 2023 May 9;12(5):881. doi: 10.3390/antibiotics12050881. PMID: 37237784; PMCID: PMC10215628. 2. Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO. Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan;344(1):113-23. doi: 10.1124/jpet.112.197905. Epub 2012 Sep 25. PMID: 23010362.
In vivo protocol:
1. Lim R, Carberry JC, Wellman A, Grunstein R, Eckert DJ. Reboxetine and hyoscine butylbromide improve upper airway function during nonrapid eye movement and suppress rapid eye movement sleep in healthy individuals. Sleep. 2019 Apr 1;42(4):zsy261. doi: 10.1093/sleep/zsy261. PMID: 30590857; PMCID: PMC8453808. 2. Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka DT. Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers. J Psychiatry Neurosci. 2014 May;39(3):E24-31. doi: 10.1503/jpn.130131. PMID: 24467942; PMCID: PMC3997609.
Wośko S, Serefko A, Szopa A, Kardaś S, Widelski J, Mroczek T, Rostkowska E, Szymańska J, Poleszak E. Influence of Smallanthus sonchifolius (Yacon) on the Activity of Antidepressant Drugs in Mice. Life (Basel). 2021 Oct 21;11(11):1117. doi: 10.3390/life11111117. PMID: 34832993; PMCID: PMC8624190. Sołek P, Mytych J, Tabęcka-Łonczyńska A, Koziorowski M. Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects. Int J Mol Sci. 2021 Nov 1;22(21):11855. doi: 10.3390/ijms222111855. PMID: 34769286; PMCID: PMC8584852. 1: Mergui J, Jaworowski S. Risperidone-Induced Nocturnal Enuresis Successfully Treated With Reboxetine. Clin Neuropharmacol. 2016 Mar 17. [Epub ahead of print] PubMed PMID: 26992158. 2: Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016 May;144:7-12. doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15. PubMed PMID: 26892759. 3: Witten L, Bastlund JF, Glenthøj BY, Bundgaard C, Steiniger-Brach B, Mørk A, Oranje B. Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol. Neuropsychopharmacology. 2016 Jan;41(2):638-45. doi: 10.1038/npp.2015.194. Epub 2015 Jul 1. PubMed PMID: 26129678. 4: Bozkurt H, Şahin S. Weight Loss Associated with Reboxetine Use in Adolescents. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):82-3. doi: 10.1089/cap.2015.0199. Epub 2016 Jan 27. PubMed PMID: 26881861. 5: Roni MA, Rahman S. Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacol Biochem Behav. 2015 Dec;139(Pt A):1-6. doi: 10.1016/j.pbb.2015.10.006. Epub 2015 Oct 9. PubMed PMID: 26455278. 6: Popławska M, Wróblewska D, Borowicz KK. Interactions between an antidepressant reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic seizures. Pharmacol Rep. 2015 Dec;67(6):1141-6. doi: 10.1016/j.pharep.2015.04.016. Epub 2015 May 9. PubMed PMID: 26481533. 7: Braithwaite R. Reboxetine has no antidepressant effect at all. BMJ. 2015 Nov 3;351:h5842. doi: 10.1136/bmj.h5842. PubMed PMID: 26531816. 8: Caudill MM, Hunter AM, Cook IA, Leuchter AF. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder. Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi: 10.1177/1550059414532443. Epub 2014 Sep 24. PubMed PMID: 25258429. 9: Kruchinina AD, Gengin MT. [Effect of reboxetine on activity of carboxypeptidase E in the nerve tissue of rats]. Biomed Khim. 2015 Sep-Oct;61(5):657-60. doi: 10.18097/PBMC20156105657. Russian. PubMed PMID: 26539877. 10: Metzger CD, Wiegers M, Walter M, Abler B, Graf H. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects. Int J Neuropsychopharmacol. 2015 Jul 25;19(2). pii: pyv080. doi: 10.1093/ijnp/pyv080. PubMed PMID: 26209860; PubMed Central PMCID: PMC4772816. 11: Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21. Review. PubMed PMID: 25415763. 12: Penmatsa A, Wang KH, Gouaux E. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol. 2015 Jun;22(6):506-8. doi: 10.1038/nsmb.3029. Epub 2015 May 11. PubMed PMID: 25961798; PubMed Central PMCID: PMC4608549. 13: Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases. J Clin Psychopharmacol. 2015 Jun;35(3):354-5. doi: 10.1097/JCP.0000000000000301. PubMed PMID: 25822478. 14: Gray VC, Hughes RN. Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats. Behav Brain Res. 2015 Mar 15;281:43-54. doi: 10.1016/j.bbr.2014.12.023. Epub 2014 Dec 16. PubMed PMID: 25523028. 15: Hughes S, Hickey L, Donaldson LF, Lumb BM, Pickering AE. Intrathecal reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring spinal noradrenergic inhibitory tone. Pain. 2015 Feb;156(2):328-34. doi: 10.1097/01.j.pain.0000460313.73358.31. PubMed PMID: 25599454. 16: Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS. The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. J Neurosci Res. 2015 Jan;93(1):104-20. doi: 10.1002/jnr.23473. Epub 2014 Aug 21. PubMed PMID: 25146499. 17: Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychol Med. 2014 Oct;44(13):2855-66. doi: 10.1017/S0033291714000221. Epub 2014 Mar 3. PubMed PMID: 25065692; PubMed Central PMCID: PMC4131263. 18: Graf H, Wiegers M, Metzger CD, Walter M, Grön G, Abler B. Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects. Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu004. doi: 10.1093/ijnp/pyu004. PubMed PMID: 25612894; PubMed Central PMCID: PMC4368880. 19: Bruno A, Zoccali R, Bellinghieri PM, Pandolfo G, De Fazio P, Spina E, Muscatello MR. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. J Clin Psychopharmacol. 2014 Oct;34(5):620-3. doi: 10.1097/JCP.0000000000000196. PubMed PMID: 25118083. 20: Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551. PubMed PMID: 25004184.